d[Cha4]-AVP is a potent and selective Vasopressin (AVP) V1b receptor agonist with a Ki value of 1.2nM, 151nM for V1b and V1a receptors, respectively[1]. d[Cha4]-AVP regulates the level of cAMP and increases intracellular calcium ions by activating the V1b receptor[2]. d[Cha4]-AVP has been widely used to promote the release of adrenocorticotropic hormone (ACTH) from rat anterior pituitary cells[3].
References:[1] Cheng L L, Stoev S, Manning M, et al. Design of Potent and Selective Agonists for the Human Vasopressin V1b Receptor Based on Modifications of [Deamino-Cys] arginine Vasopressin at Position 4[J]. Journal of medicinal chemistry, 2004, 47(9): 2375-2388.
[2] Griffante C, Green A, Curcuruto O, et al. Selectivity of d [Cha4] AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist[J]. British journal of pharmacology, 2005, 146(5): 744-751.
[3] Perdonà E, Arban R, Griffante C. Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells[J]. European journal of pharmacology, 2012, 679(1-3): 16-23.